|
gptkbp:instanceOf
|
gptkb:synthetic_cannabinoid
|
|
gptkbp:agonistOf
|
gptkb:CB1_receptor
gptkb:CB2_receptor
|
|
gptkbp:bindingAffinityCB1
|
42 nM
|
|
gptkbp:bindingAffinityCB2
|
8.5 nM
|
|
gptkbp:CASNumber
|
824959-81-1
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:naphthoylindole
gptkb:cannabinoid_receptor_agonist
|
|
gptkbp:chemicalFormula
|
C24H23NO
|
|
gptkbp:discoveredBy
|
gptkb:John_W._Huffman
|
|
gptkbp:firstSynthesized
|
1990s
|
|
gptkbp:IUPACName
|
(1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
|
|
gptkbp:legalStatus
|
Schedule I controlled substance in the United States
Class B drug in the United Kingdom
|
|
gptkbp:molecularWeight
|
341.45 g/mol
|
|
gptkbp:namedAfter
|
gptkb:John_W._Huffman
|
|
gptkbp:PubChem_CID
|
44418338
|
|
gptkbp:relatedTo
|
gptkb:JWH-018
gptkb:JWH-073
gptkb:JWH-250
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
|
|
gptkbp:sideEffect
|
unknown in humans
|
|
gptkbp:smiles
|
C1=CC=C2C(=C1)C=CC=C2C(=O)C3=CN(C4=CC=CC=C34)CCN5CCOCC5
|
|
gptkbp:toxicity
|
not well studied in humans
|
|
gptkbp:UNII
|
6K1V7S2F1S
|
|
gptkbp:usedFor
|
gptkb:scientific_research
|
|
gptkbp:bfsParent
|
gptkb:JWH_cannabinoids
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JWH-200
|